Mallia Secures European Patent Covering sCD83 for Hair Growth and Wound Healing
|
EQS-News: Mallia Innovations
/ Key word(s): Patent
Mallia Secures European Patent Covering sCD83 for Hair Growth and Wound Healing
Erlangen, Germany, June 11, 2025 – Mallia Innovations GmbH today announced that the European Patent Office (EPO) has granted a patent for the use of the soluble CD83 (sCD83) protein for hair growth, wound healing, hair and skin care. This patent covers the therapeutic and cosmetic application of sCD83, which has demonstrated strong potential in promoting hair growth through a multimodal mode of action. European Patent No. 4,135,745 encompasses the local and systemic use of sCD83 for therapeutic hair growth applications, which could help treat conditions such as androgenetic alopecia (AGA) and alopecia areata (AA), and therapeutic wound healing, for instance in patients with chronic diabetic wounds and hard to heal wounds. Further, the patent covers cosmetic use of sCD83, which could help people desiring fuller hair and/or longer eyelashes. sCD83 operates via multimodal mechanisms: it induces an anti-inflammatory environment at the hair follicle, inhibits its cell death and directly stimulates follicular stem cells, promoting new hair growth and strengthening hair thickness. sCD83 was first discovered more than 20 years ago by Mallia-cofounder Prof. Dr. Alexander Steinkasserer, Head of the Department of Immune Modulation at Universitätsklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), as an immune modulating molecule.[1] His work led to the discovery of the wound-healing properties of sCD83 as well as to the serendipitous finding of its potent hair growth-promoting function.[2] The patent was granted to the Friedrich-Alexander-Universität Erlangen-Nürnberg and Mallia Innovations is the exclusive license holder. “Securing this patent is a significant milestone for Mallia and confirms the novelty of our approach,” said Prof. Dr. Alexander Steinkasserer, Co-founder and Managing Director of Mallia Innovations. “sCD83 has potential to be developed as novel therapeutics and cosmetic products to help people suffering from hair loss, chronic wounds or simply desiring to improve their hair thickness. This strengthens the ongoing development efforts of Mallia, from therapeutic solutions for patients to science-based cosmetic care.” “As President, I am not only proud of our researchers’ strength in innovation, but also of the entrepreneurial spirit at FAU,” added Prof. Dr. Joachim Hornegger, President of Friedrich-Alexander-Universität Erlangen-Nürnberg. “Companies like Mallia that emerge from the research environment at FAU are an important part of the innovation ecosystem in the Metropolitan Region. I would like to wish Professor Steinkasserer all the very best and continued success with his company.” Mallia's preclinical studies have shown that topical application of sCD83 can effectively stimulate hair growth without systemic side effects, addressing the limitations of current treatments that can involve side effects such as systemic immunosuppression. About sCD83 Soluble CD83 (sCD83) is an immunomodulatory protein that is currently being developed for the topical treatment of hair loss (MAL‑856) and stimulation of hair growth (MAL‑838). The soluble CD83 protein was first identified in 2001 by Mallia co-founder Prof. Dr. Steinkasserer. It has anti-inflammatory properties via the induction of inflammation resolution, which promotes wound healing and induces new hair growth.2 In addition, sCD83 has been shown to activate regulatory T cells (Tregs)[3], which interact directly with hair follicles and can activate them.[4] Furthermore, sCD83 inhibits cell death of hair follicles and directly activates follicular stem cells, thereby stimulating new hair growth. This multimodal mode of action distinguishes sCD83 from other topically applied hair growth agents. Topically applied, sCD83 can directly reach the hair follicles but does not penetrate through the skin and thus does not enter the bloodstream. The effect is localized, which is a major advantage over systemic treatment options, which can cause severe side effects. About hair loss Hormone-related hair loss in men and women (androgenetic alopecia, or AGA) is the most common form of hair loss. Worldwide, more than 70% of men and 50% of women post menopause are affected by androgenetic alopecia. Another 147 million people suffer from immune-related, circular hair loss (alopecia areata, or AA[5],[6]). Androgenetic alopecia usually progresses gradually and is due to genetic and hormonal factors. In men, it often leads to a receding hairline and baldness on the top of the head, while in women it causes thinning hair in the parting area. Alopecia areata causes circular hair loss on the scalp, face or other parts of the body. It occurs when the immune system erroneously attacks hair follicles, leading to immune-mediated hair loss. About Mallia Mallia Innovations GmbH, based in Erlangen, Germany, is the holding company strategically driving the development and commercialization of cosmetic applications and biopharmaceutical therapies of the immune modulatory sCD83 protein, targeting hair growth, hair loss and other dermatological indications, including wound healing. Subsidiary Mallia Aesthetics GmbH focuses on the development of cosmetic products to stimulate hair growth. Based on the sCD83 protein, innovative cosmetic products are being developed and marketed to specialists and consumers. Subsidiary Mallia Therapeutics GmbH focuses on the clinical development of novel therapies for patients suffering from androgenetic alopecia or alopecia areata, among other conditions. Mallia Therapeutics' approach is also based on the scientifically proven immune modulatory mode of action of sCD83, which has been investigated for more than 25 years by Mallia co‑founder Prof. Dr Alexander Steinkasserer.1 For more information, visit www.mallia.com, follow us on LinkedIn, and contact MC Services for high resolution pictures of the leadership team.
[1] Lechmann, M., Krooshoop, D. J., Dudziak, D., Kremmer, E., Kuhnt, C., Figdor, C. G., ... & Steinkasserer, A. (2001). The extracellular domain of CD83 inhibits dendritic cell–mediated T cell stimulation and binds to a ligand on dendritic cells. The Journal of experimental medicine, 194(12), 1813-1821. DOI: 10.1084/jem.194.12.1813 [2] Royzman, D., Peckert-Maier, K., Stich, L., König, C., Wild, A. B., Tauchi, M., ... & Steinkasserer, A. (2022). Soluble CD83 improves and accelerates wound healing by the induction of pro-resolving macrophages. Frontiers in Immunology, 13, 1012647. DOI: 10.3389/fimmu.2022.1012647 [3] Bock, F., Rössner, S., Onderka, J., Lechmann, M., Pallotta, M. T., Fallarino, F., ... & Zinser, E. (2013). Topical application of soluble CD83 induces IDO-mediated immune modulation, increases Foxp3+ T cells, and prolongs allogeneic corneal graft survival. The Journal of Immunology, 191(4), 1965-1975. DOI: 10.4049/jimmunol.1201531 [4] Ali, N., Zirak, B., Rodriguez, R. S., Pauli, M. L., Truong, H. A., Lai, K., ... & Rosenblum, M. D. (2017). Regulatory T cells in skin facilitate epithelial stem cell differentiation. Cell, 169(6), 1119-1129. DOI: 10.1016/j.cell.2017.05.002 [5] Feinstein, R. P. (2022). Androgenetic alopecia.: https://emedicine.medscape.com/article/1070167-overview [6] Mostaghimi, A., Gandhi, K., Done, N., Ray, M., Gao, W., Carley, C., ... & Sikirica, V. (2022). All-cause health care resource utilization and costs among adults with alopecia areata: A retrospective claims database study in the United States. Journal of Managed Care & Specialty Pharmacy, 28(4), 426-434: DOI: 10.18553/jmcp.2022.28.4.426
11.06.2025 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group. |
2153354 11.06.2025 CET/CEST
P R O D U C T S U G G E S T I O N S
The information presented here has been provided by our content partner EQS-Group. The originator of the news is the respective issuer, the company relating to the news, a publication service provider (press or information agency) which uses the distribution service of EQS to transmit company news to shareholders, investors, investors or interested parties. The original publications and other company-relevant information can be found at eqs-news.com.
The information you can access does not constitute investment advice. The presentation of our cooperation partners, where the implementation of investment decisions would be possible depending on the individual risk profile, is solely at the discretion of the person using the service. We only present companies of which we are convinced that the range of services and customer service will satisfy discerning investors.
If you are considering leverage products, familiarise yourself with the typical characteristics of the financial instruments beforehand. Take the time to determine the risk content of the planned investment before making an investment decision. Bear in mind that a total loss cannot be ruled out with leverage products.
For newcomers to the subject, we offer various options in both the training and the tools section, through which you can train theoretical knowledge and practical experience and thus improve your skills. The offer ranges from participation in webinars to personal mentoring. The range is continuously being expanded.
1 Lab features are usually functionalities that emerge from the think tank of the investor community. In the early stages, these are experimental functionalities whose development process is largely determined by use and the resulting feedback from the community. When integrating external services or functionalities, the functionality can only be guaranteed to the extent that the individual process elements, such as interfaces, interact with each other.